FOLH1 and prostate cancer: Enrollment is ongoing in a multicenter Department of Defense and Prostate Cancer Foundation-sponsored study testing the concept of salvage targeted anti-PSMA-based RIT (http://www.clinicaltrials.gov/ct2/show/NCT00859781/).